Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 177 (Search time: 0.013 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2013Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patientsRoss, D.; O'Hely, M.; Bartley, P.; Dang, P.; Score, J.; Goyne, J.; Sobrinho-Simoes, M.; Cross, N.; Melo, J.; Speed, T.; Hughes, T.; Morley, A.
2017CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patientsBarratt, D.; Cox, H.; Menelaou, A.; Yeung, D.; White, D.; Hughes, T.; Somogyi, A.
2018Role of the β common (βc) family of cytokines in health and diseaseHercus, T.; Kan, W.; Broughton, S.; Tvorogov, D.; Ramshaw, H.; Sandow, J.; Nero, T.; Dhagat, U.; Thompson, E.; Tung Shing, K.; McKenzie, D.; Wilson, N.; Owczarek, C.; Vairo, G.; Nash, A.; Tergaonkar, V.; Hughes, T.; Ekert, P.; Samuel, M.; Bonder, C.; et al.
2014Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibHughes, T.; Saglio, G.; Kantarjian, H.; Guilhot, F.; Niederwieser, D.; Rosti, G.; Nakaseko, C.; De Souza, C.; Kalaycio, M.; Meier, S.; Fan, X.; Menssen, H.; Larson, R.; Hochhaus, A.
2009Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phaseHughes, T.; Saglio, G.; Branford, S.; Soverini, S.; Kim, J.; Muller, M.; Martinelli, G.; Cortes, J.; Beppu, L.; Gottardi, E.; Dongho, K.; Erben, P.; Shou, Y.; Haque, A.; Gallagher, N.; Radich, J.; Hochhaus, A.
2009A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed/refractory Ph plus ALLTojo, A.; Usuki, K.; Urabe, A.; Maeda, Y.; Kobayashi, Y.; Jinnai, I.; Ohyashiki, K.; Nishimura, M.; Kawaguchi, T.; Tanaka, H.; Miyamura, K.; Miyazaki, Y.; Hughes, T.; Branford, S.; Okamoto, S.; Ishikawa, J.; Okada, M.; Usui, N.; Tanii, H.; Amagasaki, T.; et al.
2010Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?Fitter, S.; Vandyke, K.; Schultz, C.; White, D.; Hughes, T.; Zannettino, A.
2003Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaO'Brien, S.; Guilhot, F.; Larson, R.; Gathmann, I.; Baccarani, M.; Cervantes, F.; Cornelissen, J.; Fischer, T.; Hochhaus, A.; Hughes, T.; Lechner, K.; Nielsen, J.; Rousselot, P.; Reiffers, J.; Saglio, G.; Shepherd, J.; Simonsson, B.; Gratwohl, A.; Goldman, J.; Kantarjian, H.; et al.
2003Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaHughes, T.; Kaeda, J.; Branford, S.; Rudzki, Z.; Hochhaus, A.; Hensley, M.; Gathmann, I.; Bolton, A.; van Hoomissen, I.; Goldman, J.; Radich, J.
2013European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Baccarani, M.; Deininger, M.; Rosti, G.; Hochhaus, A.; Soverini, S.; Apperley, J.; Cervantes, F.; Clark, R.; Cortes, J.; Guilhot, F.; Hansen-Hjorth, H.; Hughes, T.; Kantarjian, H.; Kim, D.; Larson, R.; Lipton, J.; Mahon, F.; Martinelli, G.; Mayer, J.; Muller, M.; et al.